BD – Becton, Dickinson and Company ̶ is two years into its BD2025 strategy, a plan to refocus the company on high-value growth areas while also simplifying its structure. This has among other things meant the selective acquisition of assets and the disposal of products, product lines of entire businesses that no longer fit the criteria set out in the strategy.
Podcast: BD’s Polen Pursues ‘True North’ Path To High-Value Growth
With 17 M&A successes to date, BD CEO pledges to build and simplify
In this Medtech Insight special podcast recorded in June, BD’s chief executive since January 2020, Tom Polen, describes how he has built on the legacy of his predecessor to ensure the $20bn company he now heads can grow sustainably to meet the changing demands of the health care market and the modern challenges medtech managers must face.
More from In Vitro Diagnostics
• By
The Cologuard Plus test has a sensitivity of 95% and a specificity of 94% for the detection of colorectal cancer; “unmatched accuracy,” according to Exact Sciences.
• By
A federal judge in Texas delivered what is most likely a fatal blow to the US FDA’s final rule, which would have regulated lab-developed tests as medical devices.
• By
The urine-based GAGome test showed promise in the first clinical results from the international AURORAX-0087A, in the largest study conducted on clear cell renal cell carcinoma, the most common type of kidney cancer.
• By
A new set of clinical lab regulations, which came into effect in January, include higher fees, an expanded set of possible consequences for labs that are not in compliance, and revised employee standards.
More from Diagnostics
• By
Cambridge, UK-based breath biopsy company Owlstone Medical will apply its volatile organic compound analysis platform in an attempt to develop a test for the identification and monitoring of pseudomonas aeruginosa in patients with cystic fibrosis.
• By
The urine-based GAGome test showed promise in the first clinical results from the international AURORAX-0087A, in the largest study conducted on clear cell renal cell carcinoma, the most common type of kidney cancer.
• By
Roche Diagnostics CEO Matthew Sause tells Medtech Insight about how the technology addresses the pricing challenges for mid- and low-throughput customers.